72 277

Cited 4 times in

PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis

Authors
 Bo Seong Yun  ;  Seyeon Won  ;  Ju-Hyun Kim  ;  Nara Lee  ;  Miseon Kim  ;  Mi Kyoung Kim  ;  Mi-La Kim  ;  Yong Wook Jung  ;  Ji Young Kim  ;  Seok Ju Seong  ;  Eunah Shin 
Citation
 JOURNAL OF OVARIAN RESEARCH, Vol.15(1) : 41, 2022-04 
Journal Title
JOURNAL OF OVARIAN RESEARCH
Issue Date
2022-04
MeSH
Carcinoma, Endometrioid* ; Carcinoma, Ovarian Epithelial ; Endometriosis* ; Female ; Genital Neoplasms, Female* ; Humans ; Ovarian Neoplasms* / pathology ; PAX2 Transcription Factor ; PAX8 Transcription Factor
Keywords
Borderline tumor ; Endometrioid ; Endometriosis ; PAX2 ; PAX8 ; PR ; Seromucinous
Abstract
Background: Ovarian "seromucinous carcinoma" has been recently removed in 2020 5th Edition of WHO classification of Female Genital Tumors and is considered as a subtype of endometrioid carcinoma with mucinous differentiation, while "seromucinous borderline tumor" remains and exists as a distinct entity. Both diseases may be considered as no more same lineage. However, ovarian seromucinous borderline tumor (SMBT) is also one of the endometriosis-related neoplasm of ovary similar to endometrioid tumor, featuring that about 50% of ovarian SMBTs combine endometriosis. The present study was aimed to investigate whether the ovarian SMBTs are different in clinical features and molecular patterns, according to the presence of combined endometriosis.

Results: There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis (P = 0.016, P < 0.001). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (P = 0.018), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups.

Conclusions: Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship.
Files in This Item:
T202201632.pdf Download
DOI
10.1186/s13048-022-00975-5
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Shin, Eunah(신은아)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188800
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links